Abstract: A lift chair frame is disclosed having an adjustable seat including a front support bar assembly including a left member and a right member connected to the left member, a rear support bar assembly opposite the front support bar assembly along a longitudinal direction, a left support bar connected to the front and rear support bar assemblies, and a right support bar opposite the left support bar along a lateral direction that is perpendicular to the longitudinal direction and connected to the front and rear support bar assemblies.

Abstract: A sleep system comprises at least one mattress including a first sleep area for a first occupant, the first sleep area including a first section for a portion of a body of the first occupant, and a second sleep area adjacent to the first sleep area for a second occupant, the second sleep area including a second section for a portion of a body of the second occupant, an articulation system for articulating the first section and the second section, a first user controller configured to communicate with the articulation system in order to control articulation of the first section, and a second user controller configured to communicate with the articulation system in order to control articulation of the second section, wherein the first user controller is further configured to communicate with the articulation system in order to move the second section into a predetermined position.

Abstract: A patient bed is provided in a healthcare facility having a network including a real time locating system (RTLS) and an electronic medical records (EMR) computer. The patient bed includes bed control circuitry that is configured to receive at least one protocol messages from the EMR computer and, in response to the at least one protocol message, enables at least one bed safety protocol in which at least one bed condition is monitored by the bed control circuitry. The bed control circuitry generates an alert in response to the at least one bed condition being in an undesirable state and no caregiver being present in the patient room as determined by the RTLS and communicated to the bed circuitry. The bed control circuitry suspends monitoring the at least one bed condition in response to the RTLS indicating to the bed control circuitry that at least one caregiver is present in the patient room.

Abstract: A rail cover assembly includes first and second cover portions coupled to one another. The first and second cover portions have surface regions made from an antimicrobial material. The first cover portion has opposing and longitudinally-extending L-shaped lips. The second cover portion has opposing longitudinal edges for nesting with the first cover portion's lips.

Abstract: A system for surrendering a baby includes a receptacle defining a space large enough to contain a baby. The receptacle includes a front located on an exterior wall of a building and an opposing back accessible from the interior of the building. An exterior door is arranged in the front and a second door is located in the back and sized to allow a baby to pass out of the receptacle. The system includes a multi-level alarm system arranged to activate when the baby is placed in the receptacle, the multi-level alarm system including a first alarm that is actuated upon opening of the exterior door and a second alarm that is actuated when the baby is placed in a medical bassinet located in the receptacle. When the exterior door is opened the first alarm sounds and when the baby is placed in the medical bassinet the second alarm sounds.

Abstract: A device (4) aligns and connects a housing hood (3) to a housing (2). The device (4) has a first connecting piece (5) and a second connecting piece (6). The first connecting piece (5) has a clamp bearing element (51) and the second connecting piece (6) has a lamella element (61). The lamella element (61) is arranged movably along the clamp bearing element (51). The device (4) has a clamping element (7) for clearance-free clamping the lamella element (61) with the clamp bearing element (51). An alignment of the hood (3) on a housing (2) can be carried out simply and rapidly and requires only weak clamping forces.

Abstract: Examination or procedure tables and chairs which can be moved into positions in more efficient and desirable ways to better meet the needs of the patient and medical service providers. In particular, a plurality of actuators which cause the seat, leg rest and foot rest of the table or chair to move and which may, if desired, be independently programmed to provide mechanically independent movement of the seat, leg rest and foot rest to desirable positions needed to provide ease of entry or transfer by the patient to the equipment including positioning the highest portion of the seat to a home or patient entry position no more than nineteen inches from the floor.

Abstract: A fascial abrasion technique tool is provided having at least one treating surface, wherein the treating surface is provided with a textured surface, so as to assist in massaging the fasica of a patient. The textured surface can be provided by a series of ridges and grooves on the edge surface, but more preferably, is provided by grid-blasting of the edge surface to produce pitting of the edge surface. Preferably, the entire tool is provided with a textured surface. The tool provides improved ability for a therapist to provide fascial abrasion therapy.

Abstract: The present invention is an apparatus for reducing the stresses applied to the hands of a therapist and improving the ability of the therapist to accurately apply a desired level of pressure to a patient when performing massage therapy on that patient.

Abstract: Various embodiments of systems, devices, components, and methods for providing external therapeutic vibration stimulation to a patient are disclosed and described. Therapeutic vibration stimulation is provided to at least one location on a patient's skin, or through clothing or a layer disposed next to the patient's skin, and is configured to trigger or induce resonance or high amplitude oscillations in a cardiovascular system of the patient. Inducing such resonance can aid in training autonomic reflexes and improve their functioning.

Abstract: A vibration device 10 includes top plate assembly 12 defining cavity 27 therein that is configured and dimensioned to receive actuator plate 19 such that the actuator plate 19 is in direct contact with the top plate assembly 12. The actuator plate 19 transmits thereby a vibration signal represented by an oscillating vibratory force to the top plate assembly 12 to operate the oscillating vibration device. Vibration device 10 further includes base plate assembly 14 for the vibration device 10. The top plate assembly 12 is configured and dimensioned to be mounted on the base plate assembly 14. The base plate assembly 14 includes actuator mounting assembly 20 that is configured to receive actuator 50 generating a vibration signal represented by an oscillating vibratory force. A method of operating the oscillating vibration device 10 includes transmitting a vibration signal represented by an oscillating vibratory force to foot plate assembly 12.

Abstract: The invention is guiding means that are adapted to serve as guides to accurately locate specific locations on the body to be stimulated in order to prevent, diagnose, and treat specific types of diseases and other conditions in humans and animals. The invention includes specially modified and personalized articles of clothing and an apparatus for supporting an organ of a human or animal body adapted for accurately positioning and orienting the organ with respect to each other a device for administering the stimulation or the healing process. The apparatus and embodiments of the articles of clothing are adapted as stands that support devices used to apply stimulation to the location. The applied stimulation can be any of the therapies which depend on the application of energy or force to specific locations on the body.

Abstract: The present invention relates to stable premix formulations for parenteral use and packaging for such formulations. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing premixed injectable formulations which remain stable during the storage period. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing dexmedetomidine premixed formulations. Such stable premixed formulations packed into a single layer or multilayer film bags comprising polypropylene are highly advantageous since they are ready-to-use, for example, in perioperative care of a subject in need thereof for sedation.

Abstract: An automatic or semi-automatic preparation system and process is provided for forming a medicament solution from a vial containing one of a liquid and a non-liquid material.

Abstract: One aspect of this disclosure provides a medication fulfillment canister. In one embodiment, the canister comprises a bottom section having a tray portion for receiving a medication therein. An upper dispensing compartment is located over a rearward end of the bottom section that is removably attached to the bottom section. A lower edge of the upper dispensing compartment is located above the bottom section to form an opening therebetween to allow a medication to pass therethrough and into the tray portion. A tray lid is removably attached to the canister and configured to cover the tray portion and rotate between an open position and a closed position. A lock is located within a wall of the bottom section that locks the tray lid in the closed position.

Abstract: A medication guidance system that securely stored blister packs as well as keep accurate inventory of specific medication within the blister packs. The medication guidance system includes a drawer housing, a blister pack drawer, a latch mechanism, a plurality of light sources, a plurality of cameras, and a microcomputer. The drawer housing is the structural body and holds the blister pack drawer through a drawer hole. The blister pack drawer is slidably positioned within the drawer hole. The light sources and the cameras are positioned within the drawer housing and oriented towards the blister pack drawer to visually identify the contents placed within the blister pack drawer. The data taken by the cameras is graphically analyzed by the microcomputer for inventory and identification purposes. The latch mechanism is mechanically integrated in between the drawer housing and the blister pack drawer to manage access to the blister pack drawer.

Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.

Abstract: The disclosure provides a disposal device for receiving and storing an oral waste product. The disposal device includes a waste container having a first opening for passage of the oral waste product into and out of the container. The disposal device includes a mouthpiece having a first end, a second end, and an interior channel extending from the first end to the second end. The mouthpiece is for a user to spit the oral waste product into the first end and for the oral waste product to exit at the second end. The disposal device includes a waste tube for passage of the waste product from the mouthpiece to the waste container. The waste tube has a first opening and a second opening. The first opening is sealingly coupled to the second end of the mouthpiece. The second opening is sealingly coupled to the first opening of the waste container.

Abstract: The present disclosure provides a cosmetic including a cosmetic composition having low viscosity, a receiving member in which the cosmetic composition having low viscosity is received, and a film forming member which covers an opening of the receiving member. By the use of the elastic film forming member, the cosmetic of the present disclosure may provide convenience of carrying with, reduce the container volume, and increase an amount of cosmetic composition contained, as compared to sponge impregnation material cosmetics.

Abstract: A method of preparing a vesicle for skin absorption enhancement, a vesicle prepared using the method, and a cosmetic composition including the vesicle are provided. The vesicle preparation method may provide a skin absorption enhancement effect and may be used to prepare vesicles with improved formulation stability. The vesicle prepared using the method may be safe without skin irritation and have an improved skin absorption effect due to the use of a ceramide as a skin absorption enhancer, and may have improved formulation stability due to use of a nonionic surfactant and a phospholipid. Accordingly, the vesicle may be used in cosmetic compositions for enhancing skin absorption of bioactive ingredients such as functional ingredients.

Abstract: The subject matter of the present disclosure is the use of a combination of succinic acid and ethylene carbonate in a hair bleaching agent to reduce the damage to keratinic fibers due to the oxidative hair lightening.

Abstract: An aqueous composition comprising basic aluminium chloride salt of formula Al2(OH)4.4Cl1.6 to Al2(OH)4.9Cl1.1, calcium chloride at a molar level of 0.020 or greater relative to the aluminium present, and glycine at a molar level of 0.050 or greater relative to the aluminium present, characterised in that the molar ratio of aluminium to the sum of the molar amounts of the calcium chloride and glycine is from 3.9:1 to 6.1:1 and in that the molar ratio of glycine to Al is greater than 1.7:10 and the molar ratio of Ca to Al is less than 0.35:10 or the molar ratio of Ca to Al is greater than 0.35:10 and the molar ratio of glycine to Al is less than 1.7:10.

Abstract: The present invention relates to a hair bleaching process for improved and milder bleaching, especially for bleaching human hair. The ready-to-use bleaching composition comprises carboxylic acids in addition to bleaching persalts and oxidizing agents added at the time of use.

Abstract: A method directed to a hair soaking treatment for frizz reduction comprising immersion of consumer hair into an aqueous composition is disclosed. The corresponding composition comprises from about 0.25% to 20% of a moisture control material or mixture of moisture control materials wherein the moisture control material has structure selected from the group A) wherein R is hydrogen or metal ion, R6 is methyl, ethyl, propyl, alkenyl or phenyl having less than 12 carbon atoms and wherein R7, R8, R9, R10, R11, R12 are hydrogen, methyl, ethyl, propyl, phenyl, hydroxyl, methoxy or ethoxy groups; B) an alcohol wherein R13 is an alkyl, alkenyl, straight or branched carbon chains and; and wherein R14 is hydrogen, hydroxyl, alkyl, methyl, ethyl and propyl wherein the structure of such alcohol contains less than 20 total carbon atoms; C) alcohol comprising an unsaturated double bond in the C2 position.

Abstract: The subject of the present disclosure is a method for coloring of keratinous fibers, particularly human hair, including the following steps in the specified sequence: A) Treatment of the fibers with a hydrous pre-treatment agent (V), B) Treatment of the fibers with a hydrous coloring agent (F), wherein the pre-treatment agent (V) has a pH value of from about 1.0 to about 5.0 and the coloring agent (F) has at least one partially-oxidizing acid dye and a pH value of from about 5.0 to about 9.5. An additional subject of the present disclosure is a multi-component package unit (kit) including a pre-treatment agent (V) and a coloring agent (F).

Abstract: A supplement composition formulated to support the health of a human's hair skin and nails containing biotin, Haematococcus pluvialis algae, and Reishi.

Abstract: A cosmetic composition for the eyes of the present disclosure contains 10.01 to 30% by mass of a silicone series film forming agent and 25 to 70% by mass of a volatile oil component with respect to the total amount of the cosmetic composition for the eyes. The amount of a volatile silicone series oil component is 25% by mass or greater with respect to the total volatile oil component, and the hardness is 30 or greater and 100 or less. The cosmetic composition has superior cosmetic lasting effects and can be utilized as both mascara and eyeliner.

Abstract: The invention relates to a copolymer resulting from the polymerization of: (i) 70% to 95% by weight, of the total weight of the monomers, of isobornyl (meth)acrylate; (ii) 1% to 30% by weight of vinylphosphonic acid monomer; (iii) 0 to 20% by weight of an additional monomer. The invention also relates to a cosmetic composition comprising the copolymer and to a cosmetic process for caring for or making up keratin materials, comprising the topical application of the composition to the keratin materials. It also relates to the use of the copolymer as a skin-tensioning agent.

Abstract: The invention provides non-aqueous compositions comprising film forming polymers comprising repeating units derived from: (a) at least one monomer comprising at least one functionalized or unfunctionalized acryloyl moiety and at least one lactam moiety; (b) at least one monomer selected from the group consisting of functionalized and unfunctionalized C1-C7 alkyl (alk)acrylates, C1-C7 alkyl (alk)acrylamides, and combinations thereof; and (c) at least one monomer selected from the group consisting of functionalized and unfunctionalized C8-C60 alkyl (alk)acrylates, C8-C60 (alk)alkyl acrylamides, and combinations thereof. The invention further provides applications of these compositions in various industrial arts, particularly in personal care. The invention furthermore provides water-resistant non-aqueous personal care compositions. Variables a, b and c are described herein.

Abstract: The present disclosure relates generally to a composition comprising at least one capped oligomer, at least one solvent, at least one film former, and at least one monomer or polymer, said composition having a sward hardness <10 and >1 when applied to a glass plate.

Abstract: A sunscreen in powder form includes vegetable oil, vegetable butter, wax or mixture thereof. Vegetable oil, vegetable butter and wax are present in a total amount of from 1 to 25% by weight of the sunscreen. One or more UV absorbing materials are present in an amount of from 10 to 40% by weight of the sunscreen. One or more UV reflecting materials are present in an amount of from 30 to 85% by weight of the sunscreen. One or more anti-caking agents are present in an amount of from 5 to 25% by weight of the sunscreen.

Abstract: A hair care composition includes a mixture including olive oil, a hair curl controlling cream, unrefined Vitellaria paradoxa (shea) butter and baby oil cream.

Abstract: This invention relates to kits that allow the user to apply cosmetic products such as creams and serums to be mixed with a subject's own platelet rich plasma (PRP) and applied to the skin for several days.

Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) and a second therapeutically active agent(s) to the back of the neck of a human patient to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the drugs are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.

Abstract: The present invention provides a microneedle device comprising: a substrate; a microneedle disposed on the substrate; and a coating layer formed on the microneedle; in which the coating layer comprises a recombinant follicle-stimulating hormone, arginine, and glycerin, in the coating layer, the mass of arginine is 0.07 to 0.75-fold of the mass of the recombinant follicle-stimulating hormone and the mass of glycerin is 0.1 to 2.75-fold of the mass of the recombinant follicle-stimulating hormone.

Abstract: The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.

Abstract: Selected anticholinergic zwitterions are administered to slow the progression of myopia in children and to treat myopia generally.

Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat, prevent from having, prevent from developing, control, reduce the severity, or reduce the progression of a disease, disorder or condition of a subject.

Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

Abstract: The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

Abstract: Disclosed is a preparation method for charge reversal and reversibly crosslinked redox-sensitive nanomicelles, falling within the technical field of biomedical materials. The method comprises: synthesizing thiocinamide from lipoic acid and ethylenediamine under an N,N?-carbonyl diimidazole catalyst; and polymerizing thiocinamide, polyethylene glycol diglycidyl ether and lysine through a nucleophilic addition mechanism to prepare a poly(lysine-co-polyethylene glycol diglycidyl ether-co-thiocinamide) terpolymer. The micelle is endowed with excellent anti-protein nonspecific adsorption and enhanced cell uptake property through a self-assembly and protonation/deprotonation action; and a disulfide bond in lipoyl may form a linear polydisulfide structure under the action of 1,4-dithiothreitol, so that a micelle core is crosslinked, and a crosslinked structure is destroyed in the cell under a redox condition, and controlled release of a drug can be achieved.

Abstract: The present disclosure provides systems and methods for the continuous production of liposomes. An example method includes (a) mixing a solution of lipid and organic solvent from one or more containers to create an organic solvent-lipid solution, (b) providing the organic solvent-lipid solution to a first inlet of an injection port at a first flow rate, wherein the first inlet is in fluid communication with a first conduit, (c) providing an aqueous solution to a second inlet of the injection port at a second flow rate, wherein the second inlet is influid communication with a second conduit, wherein the first conduit is positioned concentrically within the second conduit at an outlet of the injection port, and wherein the first conduit extends through the outlet of the injection port, and (d) mixing the organic lipid solution and the aqueous solution to create a plurality of liposomes.

Abstract: This invention relates to a granulate comprising mannitol and sorbitol in a weight ratio of between 70:30 and 97:3. This invention also relates to the use of the said granulate in the preparation of orodispersible tablets, to the orodispersible tablets obtained with the said granulate and to a process of production for obtaining the said granulate.

Abstract: The present invention provides a composite granulated product that is optimal for allowing a tablet, preferably an orally disintegrating tablet (OD tablet) to be excellent in disintegrability and have proper hardness. The composite granulated product includes a sugar or a sugar alcohol, a swelling binder, a disintegrating agent, and a highly absorbent excipient.

Abstract: The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

Abstract: The invention relates to an oral delivery vehicle tablet, the delivery vehicle tablet being formed by compression of a plurality of particles, wherein the oral delivery vehicle tablet comprises sugar alcohol(s) in an amount of 40 to 99.9% by weight of the delivery vehicle tablet, wherein the oral delivery vehicle tablet comprises non-direct compressible (non-DC) erythritol particles in an amount of 15-50% by weight of the delivery vehicle tablet, wherein the oral delivery vehicle tablet comprises one or more binders other than binders granulated to the sugar alcohol(s) in an amount of 0.1 to 6% by weight of the tablet, wherein the delivery vehicle tablet comprises a plurality of further sugar alcohol particles in an amount of at least 10% by weight of the delivery vehicle tablet and wherein said further sugar alcohols particles have a composition which is different from said non-DC erythritol.

Abstract: Disclosed a pregabalin-containing, high swellable, oral sustained-release triple layer tablet suitable for administration once daily.

Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.

Abstract: Disclosed are microspheres having a core/shell structure and a spherical shape, wherein (a) the core comprises solid-state aripiprazole, and (b) the shell coats all or most of the surface of the core, and the shell comprises a biodegradable polymer; a process for producing the microspheres; and an injectable aqueous suspension formulation containing the microspheres; and the like.

Abstract: Improved distribution can be achieved by delivering nanoparticles possessing non-adhesive surfaces via CED in a hyperosmolar infusate solution. This delivery strategy minimizes the hindrances imposed by the brain extracellular matrix and reduces the concentration of therapeutic that is confined within perivascular spaces.